(Q33364604)

26 July 2017

title

Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

1 reference

1

Yoh Watanabe

1 reference

26 July 2017

4

Hiroshi Hoshiai

1 reference

26 July 2017

Hidekatsu Nakai

2

1 reference

26 July 2017

Haruhiko Ueda

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

96

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

323-329

1 reference

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

The effect of granisetron on in vitro metabolism of paclitaxel and docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Reporting results of cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Use of tumour markers in monitoring the course of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.029

10.1016/J.YGYNO.2004.09.029

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference